"Fatty Liver" now "MASH & MASLD"

At the conclusion of this session, the participant should be able to:

1. Identify the evolving terminology and classification of fatty liver disease, including the transition from NAFLD/NASH to MASLD/MASH, and understand the implications for diagnosis and patient communication.
2. Recognize the clinical presentation, risk factors, and diagnostic tools for MASLD and MASH, including noninvasive assessments like FIB-4, ELF, FibroScan, and MRE, especially in patients with cardiometabolic conditions.
3. Evaluate current and emerging treatment strategies for MASH and associated cirrhosis, including lifestyle interventions, pharmacologic therapies such as Resmetirom and Tirzepatide, and the importance of screening for hepatocellular carcinoma.

ACCREDITATION

The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this activity for a maximum of 1 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.

Grievance Policy Statement

"It is the policy of the POMA that any physician dissatisfied with the CME program will be issued a refund upon request, and no CME credits will be reported to the AOA.  Complaints on Evaluation Forms also are taken into consideration when planning future CME programs and may lead to changes in the format or content."  If you have any questions or concerns about this educational experience, you may call the POMA office at (717) 939-9318 or send an email message to cme@poma.org.  All questions or concerns will be addressed promptly.